Abstract:The Leucine-rich repeat kinase-2 ( ) G2019S mutation, resulting in aberrantly enhanced kinase activity, is one of the well-recognized genetic risk factors in Parkinson’s Disease (PD). Increased LRRK2 activity was also observed in immune cells from PD patients. Emerging results have also unveiled an upsurge in α-synuclein (α-syn)-specific CD4 T cell responses in PD patients. Given that mutations in PD are germline mutations, there are unmet meets to explore whether G2019S mutation contributes to the pathogenesis of PD via altering CD4 T-cell functions. To fill this knowledge gap, we generated a new T cell receptor (TCR) transgenic mouse strain bearing G2019S knock-in mutation, OT-II/LRRK2 (Refer to Mut). As CD4 T cells from OT-II mice specifically recognize ovalbumin, this new strain enables us to explore the impact of G2019S mutation on T-cell functions in an antigen-specific manner. We found that the abundance and proliferation of major immune subsets in spleen tissue from Mut mice are comparable to wild-type (OT-II, Refer to WT) control. However, when we characterized T cell differentiation in these two strains, T cells derived from Mut mice displayed increased Th2 differentiation (IL-4) and decreased Th9 (IL-9) and Treg (Foxp3 %) differentiation. G2019S mutation significantly altered the expression levels of master transcription factors (TFs) for T cell differentiation. Specifically, Mut T cells displayed an increase in mRNA expression of (TF for Th2), a decrease in expression of and (TFs for Th9 and Treg, respectively). Mechanistically, mutation decreased IL-9 production and Treg cell population through the JAK/STAT3 signaling. In conclusion, LRRK2 plays a critical role in regulating T cell differentiation, warranting further studies to evaluate the impacts of altered T cell differentiation led by mutation in dopaminergic neuron damages.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore whether the LRRK2 G2019S mutation is involved in the pathogenesis of Parkinson's disease (PD) by changing the function of CD4+ T cells, especially the differentiation of Th9 and Treg cells. Specifically, researchers are concerned with how the LRRK2 G2019S mutation affects the T - cell differentiation process and whether this effect is mediated through the JAK/STAT3 signaling pathway. ### Background The LRRK2 (Leucine - rich repeat kinase 2) G2019S mutation is one of the known genetic risk factors for Parkinson's disease (PD). This mutation leads to an abnormally enhanced kinase activity of LRRK2. In PD patients, the activity of LRRK2 in immune cells also increases, and at the same time, the α - synuclein (α - syn)-specific CD4+ T - cell response also rises. Given that the LRRK2 mutation is a germline mutation in PD, it is of great significance to study whether it affects the pathogenesis of PD by changing the function of CD4+ T cells. ### Research Objectives 1. **Explore the impact of the LRRK2 G2019S mutation on CD4+ T - cell function**: By generating TCR transgenic mice (OT - II/LRRK2) carrying the LRRK2 G2019S mutation, study the impact of the LRRK2 mutation on T - cell differentiation. 2. **Reveal the molecular mechanism by which the LRRK2 G2019S mutation affects T - cell differentiation**: Pay special attention to whether the LRRK2 mutation inhibits the differentiation of Th9 and Treg cells through the JAK/STAT3 signaling pathway. ### Main Findings - **Altered T - cell differentiation preference**: T cells carrying the LRRK2 G2019S mutation show an increase in Th2 differentiation and a decrease in Th9 and Treg differentiation. - **Changes in transcription factor expression**: The mRNA expression of Gata3 (the main transcription factor for Th2 differentiation) in mutant T cells increases, while the expressions of Irf4 (the main transcription factor for Th9 differentiation) and Foxp3 (the main transcription factor for Treg differentiation) decrease. - **The role of the JAK/STAT3 signaling pathway**: The LRRK2 G2019S mutation inhibits the differentiation of Th9 and Treg cells through the JAK/STAT3 signaling pathway. Using the STAT3 inhibitor Stattic can restore the IL - 9 level and Irf4 mRNA level of mutant T cells under Th9 differentiation conditions and up - regulate Foxp3 expression under Treg differentiation conditions. ### Conclusion LRRK2 plays a crucial role in regulating T - cell differentiation. The LRRK2 G2019S mutation inhibits the differentiation of Th9 and Treg cells through the JAK/STAT3 signaling pathway, which may have an important impact on the pathogenesis of Parkinson's disease. These findings provide new clues for further research on how the LRRK2 mutation affects dopaminergic neuron damage by changing T - cell differentiation.

G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3

Clinical and Functional Evidence for the Pathogenicity of the LRRK2 P.arg1067gln Variant

LRRK2 G2019S variant is associated with transcriptional changes in Parkinson's disease human myeloid cells under proinflammatory environment

Age-related LRRK2 G2019S Mutation Impacts Microglial Dopaminergic Fiber Refinement and Synaptic Pruning Involved in Abnormal Behaviors

LRRK2G2019S Gene Mutation Causes Skeletal Muscle Impairment in Animal Model of Parkinson's Disease

LRRK2 Gly2019Ser Mutation Promotes ER Stress via Interacting with THBS1/TGF‐β1 in Parkinson's Disease

Dysregulated Wnt and NFAT signaling in a Parkinson's disease LRRK2 G2019S knock-in model

Enhanced Striatal Dopamine Transmission and Motor Performance with LRRK2 Overexpression in Mice is Eliminated by Familial Parkinson's Disease Mutation G2019S

Mutant LRRK2 in lymphocytes regulates neurodegeneration via IL-6 in an inflammatory model of Parkinson’s disease

α-Synuclein induces Th17 differentiation and impairs the function and stability of Tregs by promoting RORC transcription in Parkinson's disease

Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival

G2019S LRRK2 Mutation Enhances MPP+-Induced Inflammation of Human Induced Pluripotent Stem Cells-Differentiated Dopaminergic Neurons

LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression

Parkin Mutation Decreases Neurite Complexity and Maturation in Neurons Derived from Human Fibroblasts

Parkinson's-linked LRRK2-G2019S derails AMPAR trafficking, mobility, and composition in striatum with cell-type and subunit specificity

LRRK2 G2019S mutation incites increased cell-intrinsic neutrophil effector functions and intestinal inflammation in a model of infectious colitis

Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons

Differential LRRK2 Signalling and Gene Expression in WT-LRRK2 and G2019S-LRRK2 Mouse Microglia Treated with Zymosan and MLi2

Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons

LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease

Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death